Business

Eton acquires marketing rights to pediatric drug

Posted March 27, 2020 1:00 am

DEER PARK - Specialty drugmaker Eton Pharmaceuticals has acquired U.S. marketing rights to Alkindi Sprinkle from Diurnal Group plc.

Terms of the acquisition were not announced.

Alkindi Sprinkle's New Drug Application is currently under review with the U.S. Food and Drug Administration for approval as a replacement therapy for pediatric adrenal insufficiency in patients from birth to less than 17 years old.

"This product represents the largest market opportunity within our pipeline and adds a major near-term product launch," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Diurnal Group CEO Martin Whitaker added that, if approved, Alkindi Sprinkle will "provide a major breakthrough in the U.S. as the only licensed treatment specifically designed for use in children with adrenal insufficiency."

Article Comments

Article Categories
Business Communities Deer Park Health Care

Article Comments

Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.